Biotech News

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics (ARQT)Arcutis BiotherapeuticsEarnings

Q1 2026 net product revenue for ZORYVE ® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 Continued strong demand for ZORYVE despite typical Q1 seasonality, with continued growth in share of branded non-steroidal topical treatments

Related news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

Stock data

Close
26.43 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States